Metachromatic leukodystrophy

Gerald Raymond

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

MLD is a progressive, genetic demyelinating condition resulting from disruption of the action of arylsulfatase A with the accumulation of sulfated glycolipids in the nervous system of affected individuals. All the genetic leukodystrophies result in the loss of previously acquired skills, spasticity, cortical vision loss, and lead to spastic quad-riparesis with bulbar dysfunction and the diagnosis rests on the accurate biochemical or genetic diagnosis. Curative therapy has been elusive, but the use of hematopoietic stem cell transplantation offers in selected individuals the ability to arrest the disease. Symptomatic care remains a mainstay for individuals and their families who are too advanced for transplantation.

Original languageEnglish (US)
Title of host publicationTreatment of Pediatric Neurologic Disorders
PublisherCRC Press
Pages367-370
Number of pages4
ISBN (Electronic)9780849340888
ISBN (Print)0824726936, 9780824726935
StatePublished - Jan 1 2005

Fingerprint

Metachromatic Leukodystrophy
Cerebroside-Sulfatase
Aptitude
Muscle Spasticity
Hematopoietic Stem Cell Transplantation
Nervous System
Molecular Biology
Transplantation
Therapeutics
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
sulfoglycolipids

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Raymond, G. (2005). Metachromatic leukodystrophy. In Treatment of Pediatric Neurologic Disorders (pp. 367-370). CRC Press.
Raymond, Gerald. / Metachromatic leukodystrophy. Treatment of Pediatric Neurologic Disorders. CRC Press, 2005. pp. 367-370
@inbook{3259fb6bf8e7429d972484f5a683e44f,
title = "Metachromatic leukodystrophy",
abstract = "MLD is a progressive, genetic demyelinating condition resulting from disruption of the action of arylsulfatase A with the accumulation of sulfated glycolipids in the nervous system of affected individuals. All the genetic leukodystrophies result in the loss of previously acquired skills, spasticity, cortical vision loss, and lead to spastic quad-riparesis with bulbar dysfunction and the diagnosis rests on the accurate biochemical or genetic diagnosis. Curative therapy has been elusive, but the use of hematopoietic stem cell transplantation offers in selected individuals the ability to arrest the disease. Symptomatic care remains a mainstay for individuals and their families who are too advanced for transplantation.",
author = "Gerald Raymond",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "0824726936",
pages = "367--370",
booktitle = "Treatment of Pediatric Neurologic Disorders",
publisher = "CRC Press",

}

Raymond, G 2005, Metachromatic leukodystrophy. in Treatment of Pediatric Neurologic Disorders. CRC Press, pp. 367-370.

Metachromatic leukodystrophy. / Raymond, Gerald.

Treatment of Pediatric Neurologic Disorders. CRC Press, 2005. p. 367-370.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Metachromatic leukodystrophy

AU - Raymond, Gerald

PY - 2005/1/1

Y1 - 2005/1/1

N2 - MLD is a progressive, genetic demyelinating condition resulting from disruption of the action of arylsulfatase A with the accumulation of sulfated glycolipids in the nervous system of affected individuals. All the genetic leukodystrophies result in the loss of previously acquired skills, spasticity, cortical vision loss, and lead to spastic quad-riparesis with bulbar dysfunction and the diagnosis rests on the accurate biochemical or genetic diagnosis. Curative therapy has been elusive, but the use of hematopoietic stem cell transplantation offers in selected individuals the ability to arrest the disease. Symptomatic care remains a mainstay for individuals and their families who are too advanced for transplantation.

AB - MLD is a progressive, genetic demyelinating condition resulting from disruption of the action of arylsulfatase A with the accumulation of sulfated glycolipids in the nervous system of affected individuals. All the genetic leukodystrophies result in the loss of previously acquired skills, spasticity, cortical vision loss, and lead to spastic quad-riparesis with bulbar dysfunction and the diagnosis rests on the accurate biochemical or genetic diagnosis. Curative therapy has been elusive, but the use of hematopoietic stem cell transplantation offers in selected individuals the ability to arrest the disease. Symptomatic care remains a mainstay for individuals and their families who are too advanced for transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85056431361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056431361&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056431361

SN - 0824726936

SN - 9780824726935

SP - 367

EP - 370

BT - Treatment of Pediatric Neurologic Disorders

PB - CRC Press

ER -

Raymond G. Metachromatic leukodystrophy. In Treatment of Pediatric Neurologic Disorders. CRC Press. 2005. p. 367-370